Finland pauses use of Moderna COVID-19 vaccine in young men

Vial labelled “Moderna coronavirus disease (COVID-19) vaccine” placed on displayed EU flag is seen in this illustration picture taken March 24, 2021. REUTERS FILE PHOTO

HELSINKI — Finland will pause the use of Moderna’s COVID-19 vaccine for men born in 1991 and later due to reports of a rare

cardiovascular side effect

, the institute for health and welfare said on Thursday.

Swedish and Danish health officials had announced on Wednesday afternoon they would pause the use of the Moderna vaccine for all young adults and children.


“A Nordic study involving Finland, Sweden, Norway and Denmark found that men under the age of 30 who received Moderna Spikevax had a slightly higher risk than others of developing myocarditis,” director Mika Salminen from the health institute said.

Salminen said myocarditis, which means heart muscle inflammation, usually heals on its own in a few days. He said as a precaution Finland would only give Pfizer’s vaccine to boys and young men.


‘Buong-buo ang loob ko’: Robredo to run for president in 2022


Duterte explains reason for weekend mall visit: To meet ex-girlfriend


Sara Duterte again rejects calls to run for president, wants to complete term as mayor

A Moderna spokesperson had said late on Wednesday that company was aware of the decisions by the Swedish and Danish regulators.

“These are typically mild cases and individuals tend to recover within a short time following standard treatment and rest. The risk of myocarditis is substantially increased for those who contract COVID-19, and vaccination is the best way to protect against this.”

Regulators in the United States, EU and the World Health Organization have also said the benefits of shots based on the mRNA technology used by Moderna — and Pfizer-BioNTech — in preventing COVID-19 continue to outweigh the risks.

Subscribe to our daily newsletter

Read Next

Greece’s fire-ravaged island now racing to build flood defenses



Don’t miss out on the latest news and information.

View comments